HOW DO YOU DEMONSTRATE THE VALUE OF YOUR
STROKE CARE PLAN?
How can we increase the number of patients being treated? Can more stroke patients reach functional independence?
Find out how clinical and economic data can help you to optimize stroke care.
WHAT MEDTRONIC
OFFERS
your need a solution designed for your STORY
Comprehensive and
flexible health economics solutions suitable for
multiple stakeholders
Patient clinical benefit and cost implication estimates
for hospitals, healthcare systems and society
Training and
medical education
programs
A team of
experts, ready
to talk to you!
Click on any video to learn more about STROKE CARE ECONOMIX
Stroke Care Economix
Taking stroke care further together
Introducing
Stroke Care Economix
Stroke Care Economix
features and benefits
Stroke Care Economix
in a comprehensive stroke centre
Stroke Care Economix
and the stroke care network - telestroke
Stroke Care Economix
create awareness make decisions build momentum
generating evidence
Medtronic has supported health economics studies* in 14 countries globally since 20151-16.
Argentina, Australia, Austria, Chile, Colombia, Italy, Poland, Portugal, Russia, Saudi Arabia, Singapore, Spain, United Kingdom, United States of America
16 health economics studies across 14 countries since 2015
100% cost-effectiveness analysis concluded that mechanical thrombectomy is cost-effective or cost saving
*over 60%
of the studies have been published in peer reviewed journals or considered for reimbursement by HTA/Reimbursement authorities (Australia, Poland and Russia).
request a studyCOST-EFFECTIVENESS ANALYSIS
VALUE PER MONEY AT GLANCE
SOLITAIRE™
“Stent-retriever thrombectomy after intravenous tissue plasminogen activator is a dominant alternative over intravenous tissue plasminogen activator alone (more effective and less costly) for the treatment of acute ischaemic stroke ……” 17
“Combined stent-retriever neurothrombectomy and IV t-PA is a highly effective treatment for acute ischemic stroke and results in long-term cost-saving when compared with IV t-PA alone…” 18
“Among patients with acute ischemic stroke enrolled in the SWIFT- PRIME trial, SST increased initial treatment costs, but was projected to improve quality-adjusted life-expectancy and reduce healthcare costs over a lifetime horizon compared with tPA” “…findings suggest that for patients similar to those enrolled in SWIFT-PRIME, a treatment strategy of SST+tPA is highly cost- effective and likely economically dominant compared with tPA” 19
possible
benefits
Partner with Medtronic and focus on what matters:
The urgent care you need to provide to give patients a better chance to recover from stroke.
MEASURE PATIENT BENEFIT AND COST
IMPLICATION OF OPTIMIZING THE PATIENT
PATHWAY IN SHORT, MID AND LONG TERM
1
de Andrés-Nogales, Fernando, et al. "Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain." European Stroke Journal 2.3 (2017): 272-284.
2
Ruggeri, Matteo, et al. "Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy." Journal of Medical Economics 21.9 (2018): 902-911.
3
Lobotesis, Kyriakos, et al. "Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK." Journal of Medical Economics 19.8 (2016): 785-794.
4
Ni, Weiyi, et al. "Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective." BMJ open 10.9 (2020): e036517.
5
Lenz-Alcayaga, Rony, et al. "Cost-utility analysis: Mechanical thrombectomy plus thrombolysis in ischemic stroke due to large vessel occlusion in the public sector in Chile." Medwave 21.3 (2021): e8152-e8152.
6
Arora, Nimita, et al. "Cost-effectiveness of mechanical thrombectomy for acute ischemic stroke: an Australian payer perspective." Journal of medical economics 21.8 (2018): 799-809.
7
Al-Senani, Fahmi, et al. "A national economic and clinical model for ischemic stroke care development in Saudi Arabia: A call for change." International Journal of Stroke 14.8 (2019): 835-842.
8
Dombrovsky V. S., Ivakhnenko O. I., Avksentyeva M. V., Omelyanovskiy V. V., Musina N. Z. Efficacy and Efficiency of Mechanical Thromboextraction in Combination with Thrombolytic Therapy or as an Independent Method of Intravascular Treatment in Patients with Ischemic Stroke. Medical technologies. Evaluation and selection. 2018; 2 (32): 48–59.
9
Shireman, Theresa I., et al. "Cost-effectiveness of Solitaire stent retriever thrombectomy for acute ischemic stroke: results from the SWIFT-PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)." Stroke 48.2 (2017): 379-387.
10
Genovez, V., et al. "PCV37 Cost-Effectiveness Analysis of IV-TPA Followed By Mechanical Thrombectomy with Stent-Retriever versus IV-TPA alone in the treatment of Acute Ischemic Stroke due to Large Vessel Occlusion in Portugal." Value in Health 23 (2020): S493.
11
Pabon, B., et al. "P-018 Cost-effectiveness of endovascular stroke therapy. analysis from a Colombian healthcare perspective." (2019): A34-A35.
12
Pochopien M. et al. Cost-effectiveness analysis of mechanical thrombectomy in acute phase of ischemic stroke (AIS). Value in Health Volume 2017; 20, Issue 9, October–November 2017, Page A578.
13
Alcayaga, R. Lenz, et al. “PMD22: Budget Impact Analysis of the incorporation of mechanical thrombectomy with stent retrievers after thrombolysis in ischemic stroke with large vessel occlusion in the Chilean public sector.” Value in Health (2020), ISSN: 1098-3015, Vol: 23, Page: S192.
14
Lylyk, P., et al. "PND28 Budget Impact Analysis of the Incorporation of Mechanical Thrombectomy with Stent Retrievers after Thrombolysis in Ischemic-Stroke with Large Vessel Occlusion in Obras Sociales and Empresas De Medicina Prepaga in Argentina." Value in Health 24 (2021): S163-S164.
15
Lylyk, P., et al. "PND24 Cost-Utility of Mechanical Thrombectomy after Thrombolysis in Ischemic-Stroke due to Large Vessel Occlusion in Programa de Atencion medica Integral Pami in Argentina." Value in Health 24 (2021): S163.
16
Austria: Data on file.
17
de Andrés-Nogales, Fernando, et al. "Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain." European Stroke Journal 2.3 (2017): 272-284.
18
Lobotesis, Kyriakos, et al. "Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK." Journal of Medical Economics 19.8 (2016): 785-794.
19
Shireman, Theresa I., et al. "Cost-effectiveness of Solitaire stent retriever thrombectomy for acute ischemic stroke: results from the SWIFT-PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)." Stroke 48.2 (2017): 379-387.